Angely Loubert

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.

Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.

Journal: Current medical research and opinion

Published: January 30, 2026

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Journal: Journal of geriatric oncology

Published: September 26, 2025

Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.

Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.

Journal: Journal of patient-reported outcomes

Published: September 09, 2025

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.

Journal: The Lancet. Haematology

Published: May 23, 2025

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.

Journal: The Lancet. Haematology

Published: January 16, 2025

Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer.

Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer.

Journal: Journal of patient-reported outcomes

Published: August 09, 2024

Can patient self-evaluation of functional status be used for evaluation of impairment of motor function in Guillain-Barré syndrome? Mapping clinician- and patient-reported outcomes in a phase 3 study of eculizumab in Japan.

Can patient self-evaluation of functional status be used for evaluation of impairment of motor function in Guillain-Barré syndrome? Mapping clinician- and patient-reported outcomes in a phase 3 study of eculizumab in Japan.

Journal: Frontiers in neurology

Published: July 12, 2024

Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer's dementia.

Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer's dementia.

Journal: Frontiers in neurology

Published: March 04, 2024

Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies.

Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies.

Journal: Multiple sclerosis journal - experimental, translational and clinical

Published: February 21, 2023

Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis.

Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis.

Journal: Journal of patient-reported outcomes

Published: November 30, 2022

A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies.

A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies.

Journal: Journal of the National Cancer Institute

Published: April 14, 2022

Evaluating the impact of calibration of patient-reported outcomes measures on results from randomized clinical trials: a simulation study based on Rasch measurement theory.

Evaluating the impact of calibration of patient-reported outcomes measures on results from randomized clinical trials: a simulation study based on Rasch measurement theory.

Journal: BMC medical research methodology

Published: December 17, 2021

Showing 1-12 of 13

Last Updated: 09/26/2026